Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation

Reuters
10/17
Protalix BioTherapeutics Highlights Rare Disease Drug Pipeline and New Gout Therapy in Latest Corporate Presentation

Protalix BioTherapeutics Inc. has released a corporate presentation detailing its current pipeline and financial status. The company reported $53 million in revenue for the full year 2024 and $25.4 million in revenue from product sales in the first half of 2025. As of June 30, 2025, Protalix holds $33.4 million in cash with no debt or warrants, supporting its operations and pipeline development into 2027. Protalix highlighted its commercial portfolio, which includes approved enzyme replacement therapies for Fabry disease and Gaucher disease in the United States, European Union, and additional markets. The development portfolio features PRX-115, a PEGylated uricase candidate targeting uncontrolled gout, with a Phase 2 trial expected to begin in the fourth quarter of 2025. The company is also advancing PRX-119, a long-acting DNase I, and is pursuing additional programs in rare renal and NETs-related diseases. Over the next three years, Protalix aims to expand its pipeline to five to seven programs spanning discovery to clinical stages. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief on October 17, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10